Metformin use and respiratory outcomes in asthma-COPD overlap.

ABSTRACT:

Background

Metformin is associated with improved respiratory outcomes in asthma; however, metformin in COPD and asthma-COPD overlap (ACO) remains unexplored.

Objective

To determine the association between metformin use and respiratory outcomes in COPD and ACO.

Study design and methods

Participants with COPD (FEV1/FVC < 0.70) in the Genetic Epidemiology of COPD study (COPDGene®) were categorized as ACO (n = 510), defined as concurrent physician-diagnosed asthma before age 40 years, or COPD alone (n = 3459). We estimated the association of baseline metformin use with (1) rate of total and severe respiratory exacerbations during follow-up, (2) cross-sectional St. George's Respiratory Questionnaire (SGRQ) score, six-minute walk distance (6MWD), and post-bronchodilator FEV

SUBMITTER: Wu TD 

PROVIDER: S-EPMC7908718 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature